06185.HK
CanSino Biologics Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 29.22
−0.61%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
45.9x
EV/EBITDA
139.5x
Market Cap
HKD 7.22B
MomentumView details →
1D Return
−0.61%
YTD Return
−16.32%
RSI (14)
53.8
ValuationView details →
P/E (Fwd)
45.9x
EV/EBITDA
139.5x
Market Cap
HKD 7.22B
RSI (14)
53.8
MomentumView details →
1D Return
−0.61%
YTD Return
−16.32%
Similar companies
Latest newsMore news →
CanSino Biologics reported its first-half 2026 results, with revenue of 550 million yuan, up 43.81% year-on-year, and a net loss attributable to shareholders of 720,800 yuan, compared with a loss of 13.4854 million yuan in the same period of 2025.9d agoCanSino Biologics announced it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as InVivoCAR-related therapies, all currently in early stages.10d ago